The first patient has been treated in a phase 1/2 trial of AGN-151587, the first in vivo CRISPR medicine to be administered in patients, according to a press release from Editas Medicine.
The BRILLIANCE clinical trial is evaluating AGN-151587 (EDIT-101), an experimental CRISPR-based medicine administered via subretinal injection, in patients with Leber congenital amaurosis 10 (LCA10). It is the first gene editing medicine to be evaluated inside the body.
“This dosing is a truly historic event — for science, for medicine and most importantly for people living with this eye disease,”
Uncategorized